We previously showed that mice lacking MΦLRP1 -/-(low-density lipoprotein receptor-related protein 1 in macrophages) undergo accelerated atherosclerotic plaque formation due to changes in macrophages including increased apoptosis, decreased efferocytosis, and exaggerated transition to the inflammatory M1 phenotype. Here we sought to explore the role of macrophage low-density lipoprotein receptor-related protein 1 during regression of atherosclerosis since regressing plaques are characterized by transitioning of macrophages to M2 status as inflammation resolves.
F
atty streaks in fetal and infant human aortas are known to decline in subsequent years, 1,2 suggesting that the atherosclerotic plaque may undergo bulk regression. However, the GLAGOV trial recently showed that extreme low-density lipoprotein cholesterol lowering (to <39 mg/dL) for 76 weeks does not produce bulk plaque regression (<1% atheroma volume reduction versus comparator group). 3 Thus, regression of atherosclerotic plaques in adults may require more than merely controlling low-density lipoprotein cholesterol, and novel therapies are needed that target specific mechanisms of regression. Of the components of the atherosclerotic plaques, lipids and macrophages are the most amenable to exit it and thus, contribute to plaque shrinkage. Regression and stabilization of atherosclerosis has been achieved in mouse models via correction of dyslipidemia. [4] [5] [6] The underlying mechanisms include decreased arterial wall retention of apolipoprotein B-containing lipoproteins, 7 suppressed monocyte recruitment, 8 efflux of cholesterol from plaques, 7, 9 and egress of macrophages out of the plaque. [10] [11] [12] Although inflammation plays a critical role during atherosclerosis progression, the role of inflammatory macrophages during atherosclerosis regression has not been well studied.
Plaque macrophages undergo differentiation to a functional spectrum book-ended by the complete M1 (inflammatory) and M2 (anti-inflammatory) phenotypes. 13 Progression of atherosclerosis is characterized by a low M2/M1 macrophage ratio in the plaque, accompanied by enhanced production of inflammatory cytokines and matrix metalloproteinases. 14, 15 On the other hand, as dyslipidemia resolves, regression of atherosclerotic plaques coincides with decreased macrophage cellularity and a higher M2/M1 ratio. 16 One mechanism for decreased macrophage cellularity in plaques undergoing regression is increased macrophage egress via CCR7 (C-C chemokine receptor type 7) and its ligands CCL19 (C-C motif chemokine ligand 19) and CCL21 (C-C motif chemokine ligand 21) into the draining lymph nodes. 12, 17 However, in an adenoviral-mediated apoE complementation model of plaque regression, reduced monocyte infiltration, not CCR7-dependent egress, was the mechanism behind decreased macrophage cellularity. 8 Low-density lipoprotein receptor-related protein 1 (LRP1) is a 600-kDa multi-ligand receptor, which also binds apoE (apolipoprotein E) on incoming triglyceride-rich remnants in the hepatic sinusoid. [18] [19] [20] Deletion of macrophage LRP1 in mouse models of atherosclerosis results in accelerated plaque growth caused by (1) enhanced macrophage apoptosis via suppressed protein kinase B activation, (2) decreased efferocytosis, and (3) exaggerated necrosis. 21, 22 Macrophage LRP1 is critical for efferocytosis to the point that its deletion negates the antiatherosclerotic benefits of anti-tumor necrosis factor α inhibitor adalimumab. 23 Macrophages lacking LRP1 up-regulate secretion of the inflammatory cytokines tumor necrosis factor α, monocyte chemoattractant protein-1, and matrix metalloproteinase-9. 21, 22 Although macrophage LRP1 is clearly protective during atherosclerosis progression, its role during atherosclerosis regression is unknown, and this can be used to identify unique differences between these 2 opposite stages of plaque biogenesis.
We sought to explore the role of macrophage LRP1 during regression of atherosclerosis by placing apoE -/-mice on a high-fat diet for 12 weeks, then reconstituting their bone marrow using wild-type (WT) or MΦLRP1 -/-(low-density lipoprotein receptor-related protein 1 in macrophages) mice as donors, and finally switching them back to chow diet for 10 weeks. ApoE -/-mice reconstituted with apoE -/-marrow served as controls for baseline plaque analyses. Our results show that the lack of LRP1 expression in macrophages unexpectedly promotes atherosclerosis regression. Mice with macrophages lacking LRP1 showed less M1 macrophages in the plaque and increased CCR7-dependent egress of macrophages from the plaque. Thus, loss of macrophage LRP1 has a dual and opposite effect on plaque biogenesis depending on whether the plaque is growing or shrinking.
Clinical Perspective
What Is New?
• Our study identifies a macrophage protein, LRP1, whose deletion enhances plaque regression following correction of hyperlipidemia. • LRP1 expression is reduced in alternatively differentiated macrophages.
• LRP1 absence increases reverse cholesterol transport in vivo.
• Sterol regulatory element binding protein-dependent up-regulation of genes including C-C chemokine receptor type 7 enhances the ability of LRP1 -/-macrophages to emigrate from plaques.
• Our results support the notion that plaque regression and progression are under separate regulation.
What Are the Clinical Implications?
• Systemic interventions aimed at controlling plasma glucose, blood pressure, plasma lipids, and inflammation have minimal impact on plaque regression. • Our studies advance the field by identifying LRP1, a member of the low-density lipoprotein receptor family, as a player in regulating plaque regression when systemic conditions are kept constant.
• Although LRP1 is not likely to be a therapeutic target, its dual role in mediating inflammation and efferocytosis will improve our understanding of the pathways responsible for plaque regression.
METHODS
The data that support the findings of this study are available from the corresponding author on reasonable request.
Study Design
Eight-week-old female apoE -/-mice were fed a Western-type diet (42% kcal from fat, Teklad Custom Diets) for 12 weeks followed by lethal irradiation (900 rad) and transplantation with bone marrow from WT, MΦLRP1
-/-, apoE -/-, and apoE -/-/ MΦLRP1 -/-(DKO) mice. After bone marrow transplantation (BMT), mice were placed on chow diet. ApoE -/-recipient mice transplanted with apoE -/-bone marrow were euthanized 2 weeks post-BMT for determination of baseline aortic atherosclerosis (n=9). Ten weeks after BMT, 1 cohort of mice (n=9 to 13 for each donor genotype) was euthanized for serum lipid levels and atherosclerosis analyses, as described before. 21, 24 A second cohort of BMT mice (n=6 to 8) was studied for in vivo reverse cholesterol transport (RCT). A third cohort of BMT mice (n=4 to 5) was used to label CD11b + monocytes with 5-ethynyl-2ʹ-deoxyuridine (EdU) to measure macrophage egress during atherosclerosis regression. A fourth cohort of BMT mice (n=3 to 4) was used to determine monocyte recruitment. Animal care and experimental procedures were performed according to the regulations of the Institutional Animal Care and Usage Committee of Vanderbilt University and of Oregon Health and Science University.
Atherosclerosis Analysis
Frozen sections (10 μm) of aortic root were stained with Oil Red O as previously described. 24 Images of Oil Red O staining were analyzed using the KS300 imaging system (Kontron Elektronik GmbH).
Very-low-density lipoprotein, LDL (low-density lipoprotein), and HDL (high-density lipoprotein) were separated from pooled serum (pooled from 2 to 3 mice) using fast performance liquid chromatography. Cholesterol and triglyceride levels from serum and fast performance liquid chromatography fractions were determined by enzymatic colorimetric assays using colorimetric kits (Cholesterol Reagent and Triglycerides GPO Reagent kits; Raichem, San Diego, CA).
Western Blots
Two microliters of pooled serum, 10 μL of fast performance liquid chromatography fractions (peak for very-low-density lipoprotein or HDL), or 30 µg of whole cell lysate (protein concentrations determined via bicinchoninic acid assay; BioRad) was denatured in sample buffer (Invitrogen) containing reducing buffer (Invitrogen), phospholipase inhibitors, and protease inhibitors (Sigma). Proteins were separated with gel electrophoresis and subsequently transferred to polyvinylidene difluoride membranes. Membranes were incubated with primary antibody (1:1000) at 4°C overnight and with secondary antibody (1:10 000) at room temperature for 1 hour. Anti-mouse apolipoprotein B antibody was from Lifespan Biosciences (LS-C20729), anti-mouse apoE antibody was from Abcam (ab20874), and rabbit anti-LRP1 was from abcam (ab9255). IRDye 800CW goat anti-rabbit IgG was from LI-COR Biosciences (926-32211).
Quantifications of CCR7
+ Macrophages, M1 and M2 Macrophage Phenotypes, LRP1, Apoptosis, Efferocytosis, and
Necrosis in Atherosclerotic Plaques
Serial cryosections (5 μm) of the aortic root were used as described previously. 21, 24 Two sequential cryosections on the same glass slide were used for each staining to quantify M1 and M2 macrophages in atherosclerotic plaques. One section was stained for M2 marker arginase-1 (Arg1; Gene Tex) and CD68 (Calbiochem); the other section was stained for M1 marker arginase-2 (Arg2; Proteintech Group) and CD68. Briefly, sections were fixed in cold acetone for 10 minutes, washed twice with PBS, blocked in background buster (Innovex) at 37 o C for 1 hour, and incubated with primary antibodies at 4°C overnight. Sections were then washed with PBS 3 times, then incubated with Alexa Fluor 594 antirabbit IgG (Invitrogen) and streptavidin Alexa Fluor 488 (Life Technologies) at 37°C for 1 hour. Anti-mouse CCR7 antibody was from BD Biosciences. Images were captured using an Olympus IX81 microscope and analyzed using Adobe Photoshop CC (Mac) software. For quantification of M2 or M1 macrophages, Arg1 + or Arg2 + (red) and CD68 (green) double-positive cells were visualized with a separated color channel filter using Adobe Photoshop CC (Mac) software.
Studies of LRP1 expression in baseline and regressing plaques were performed according to the established protocol described above and using anti-rabbit LRP1 (Abcam) and anti-rat Mac-2 (Abcam).
Apoptosis was quantitated in serial cryosections (5-µm thickness) from control, WT, and MΦLRP1 -/-recipient mice undergoing regression using the In Situ Cell Death Detection Kit (Roche) according to the manufacturer's instructions. Macrophages were labeled with a Mac-2 antibody (Abcam), and efferocytosis was determined by quantifying the terminal deoxynucleotidyl transferase dUTP nick-end labeling area within Mac-2 labeled macrophages. Necrosis in atherosclerotic plaques was quantitated by measuring the Harris hematoxylin and eosin staining negative cellular area in the intima versus total intimal area using the method described previously.
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In Vitro Cholesterol Efflux
Peritoneal macrophages were collected from WT, MΦLRP1 -/-, ApoE -/-, and DKO mice 72 hours after IP injection of 3% thioglycolate. Cells were washed twice with PBS and seeded onto 24-well plates (5×10 5 cells per well). After 2 hours, nonadherent cells were removed, and plates washed with PBS twice. Cells were loaded with 3 µCi/mL 1,2-3 H-cholesterol with acetylated LDL (250 µg/mL; Alfa Aesar). Forty-eight hours later, media were removed, and cells were washed twice with PBS. Cells were equilibrated in DMEM with 0.25% BSA containing interferon-γ ([IFN-γ] 50 ng/mL, Peprotech) in DMEM overnight. The remaining cells were induced for M2 polarization using interleukin 4 (IL-4) (25 ng/mL; Sigma) or M1 polarization by IFN-γ (50 ng/mL; Peprotech) and lipopolysaccharides ([LPS]; 100 ng/mL; Sigma) in DMEM with 0.25% BSA for 3 hours. Time-0 cells were cultured in DMEM with 0.25% BSA containing IFN-γ (50 ng/mL) for the same amount of time (3 hours). After 3 hours, Time-0 cells were washed twice with PBS, air-dried, and stored at -20°C. The remaining cells were washed twice with PBS. Then cells were treated with freshly prepared M1 or M2 polarization media containing apolipoprotein A1 (50 µg/mL; Sino Biological Inc.) for cholesterol efflux for 24 hours. From each well, 120 µL of media was collected and transferred directly to multiscreen filter plate (Millipore). For radioactivity determination by liquid scintillation counting, 100 µL of media was used.
In Vivo Reverse Cholesterol Transport Assay
The in vivo RCT assay was modified from an established model by Tanigawa et al. 25 Briefly, peritoneal macrophages from WT, MΦLRP1 -/-, apoE -/-, and DKO mice were collected 72 hours after intraperitoneal injection of thioglycolate. Macrophages were first cultured in DMEM with 10% fetal bovine serum (FBS) for 2 hours. After cell attachment to plastic media, culture was switched to DMEM with 0.2% BSA overnight. Macrophages were labeled with 3 μCi/mL 3 H-cholesterol enriched with 50 μg/ mL of acetylated LDL for 48 hours to generate 3 H-cholesterol loaded foam cells. Labeled foam cells were washed twice, equilibrated in medium with 0.2% BSA for 6 hours, centrifuged, and resuspended in phenol red-free Roswell Park Memorial Institute (RPMI) medium immediately before use. BMT mice on a chow diet, as described earlier, received intraperitoneal injections of labeled foam cells of the same genotype and were fed chow diet ad libitum. After 48 hours, mice were euthanized, blood was collected by cardiac puncture, the gallbladder separated, and the liver removed and flash-frozen for lipid extraction. Feces were collected until mice were euthanized.
Serum and liver lipids were extracted as described before. 26 The lipid layer was collected, evaporated, and resuspended for scintillation counting. The gallbladder was lysed in 0.1 N NaOH for 4 hours and subjected for scintillation counting. Feces were soaked in 50 mL of 0.1 N NaOH overnight at 4 o C, and then homogenized. One milliliter of the homogenized feces was subjected to scintillation counting.
In Vivo Labeling of Bone Marrow with EdU, Isolation of CD11b + Monocytes, and Evaluation of Cell Emigration into Adjacent Lymph Nodes During Regression
Bone marrow was isolated from 7-week-old female WT, MΦLRP1
, and DKO mice after 2 weeks of IP injections of EdU (100 µg per mouse twice a week, each injection after bleeding 100 μL from the suborbital vein). CD11b + monocytes were isolated from fresh bone marrow using CD11b MicroBeads (MACS, Miltenyi Biotec), according to the manufacturer's protocol. Briefly, bone marrow was collected in RPMI phenol red-free medium with 2% FBS and 5 IU/mL heparin. Bone marrow was washed twice with RPMI supplemented with 2% FBS and then resuspended in 0.5% BSA, 2 mM ethylenediaminetetraacetic acid in 1× PBS. Cells were diluted to 1×10 7 cells/90 μL. For every 1×10 7 bone marrow cells, 10 µL of CD11b MicroBeads was added. Cells were incubated for 15 minutes on ice, washed, resuspended, and retained in the MACS LS Columns in the magnetic field of a SuperMACS separator at 4ºC. After the magnetic separation, the columns were washed, removed from the magnetic field, and dispensed into 15-mL sterile tubes using 5 mL buffer, firmly applying the supplied plunger.
A small portion of each genotype's cells was used to determine cell population using flow-cytometric analysis, and more than 98% cells were CD11b-positive. The remaining cells were resuspended in phenol red-free and serum˗free RPMI medium. Cells were injected into the third cohort of BMT mice of their respective genotype through suborbital veins. Seventy-two hours after suborbital injections, the mice were euthanized. Blood and mediastinal lymph nodes were collected to evaluate the emigration of EdU-labeled CCR7 + cells from plaque using flow cytometry. Superficial cervical lymph nodes were used as negative controls. Lymphocytes were isolated using cell strainers (70 µm Nylon, Falcon). Click-iT EdU Flow Cytometry Assay Kits (Pacific Blue azide, C10418; Invitrogen) were used for the detection of EdU. For detection of CCR7 expression, phycoerythrin-conjugated anti-mouse CD 197 (CCR7) monoclonal antibody (560682; BD Biosciences) was used.
In Vitro Analysis of Gene and Protein Expression in Polarized Macrophages
Peritoneal macrophages were collected from WT and MΦLRP1 -/-mice (n≥6) 3 days after IP injection with 3% thioglycolate, and seeded in 6-well plates at 3×10 6 cells per well in DMEM with 10% FBS. Four hours later, floating cells were removed, and attached cells were washed twice with 1× PBS. Cells were cultured in DMEM with 1% BSA overnight for macrophage synchronization. Macrophages were primed for 6 to 8 hours in DMEM with 0.1% FBS containing IFN-γ (50 ng/mL). To generate M1 macrophages, primed macrophages (Mo) were treated with IFN-γ (50 ng/mL) and LPSs (100 ng/mL) for 12 hours. To generate M2 macrophages, primed macrophages were treated with IL-4 (25 ng/mL) for 12 hours. For M1 to M2 switching, M1 macrophages were generated as described above, and then treated with IL-4 (25 ng/mL) for 12 hours to switch them to the M2 phenotype. RNA was extracted using TRIzol according to the manufacturer's protocol. Abca1, Abcg1, Srb1, Lrp1, Srebf1, Srebf2, Ccr7, Rpl32, and 18s primers were from Thermo Fisher, and quantitative real-time polymerase chain reaction (qRT-PCR) was performed using Applied Biosystems ViiA7. Experiments were performed in triplicate and repeated 3 times.
Human monocyte THP-1 cells (ATCC) were differentiated to macrophages with phorbol 12-myristate 13-acetate (10 ng/mL; Sigma-Aldrich) treatment for 48 hours. After 48 hours, phorbol 12-myristate 13-acetate-treated THP-1 cells were treated with IFN-γ and LPSs or IL-4 to generate M1 and M2 macrophages as described above.
In Vivo Monocyte Recruitment
Bone marrow was isolated from 7-week-old male WT, MΦLRP1 -/-donor mice. CD11b + monocytes were isolated from fresh bone marrow using CD11b MicroBeads (MACS) according to the manufacturer's protocol and as described above. CD11lb monocytes were labeled with Green CellTracker 5-chloromethylfluorescein diacetate (Thermo Fisher) and resuspended in phenol red-free and serum-free RPMI medium. Labeled CD11b + monocytes (2.0×10 6 ) were intravenously injected into recipient mice of their respective genotype
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undergoing regression. Seventy-two hours after injections, mice were euthanized, and aortic root serial cryosections (5 µm) were stained for CD68 and 4',6-diamidino-2-phenylindole. Monocyte recruitment was determined by counting newly recruited monocyte/macrophages positive for CD68 and normalized to lesion area.
Statistical Analyses
The Shapiro-Wilk normality test (α=0.05) was used to determine whether sample group data were distributed normally. For images, data were collected from at least 2 sections for each mouse and averaged, and none of the experimental mice were excluded from the analysis. + double-positive cell counts in mediastinal and superficial cervical control lymph nodes, we performed an ANCOVA using donor genotype as the independent variable and the paired-superficial cervical control samples as the covariate. The Tukey post hoc test was then used to report pairwise differences in mediastinal lymph nodes. Where sample size was too low or did not qualify for parametric statistics, we performed an unpaired Mann-Whitney test to determine differences between groups of 2, and the KruskalWallis using Dunn post hoc test was used for multiple groups. P<0.05 was considered significant.
RESULTS
Bone Marrow-Mediated apoE Complementation Corrects Hyperlipidemia in apoE -/-Mice
We previously demonstrated that transplanting bone marrow from apoE +/+ mice into apoE -/-recipients corrects their hypercholesterolemia and prevents atherosclerosis through the reintroduction of apoE both in plasma and in the plaque. 27 Others have shown that adenoviral-mediated reintroduction of apoE into apoE -/-mice induces atherosclerosis regression. 8 Thus, to determine whether bone marrow-mediated apoE complementation is sufficient to correct hyperlipidemia and induce regression, we performed BMT on apoE -/-mice fed a high-fat diet for 12 weeks using WT, MΦLRP1 -/-, apoE -/-, and apoE
-/-(DKO) mice as marrow donors, and then placed the recipient mice on a chow diet for 10 weeks. Serum was separated by fast performance liquid chromatography, and cholesterol levels were determined to track the different lipoprotein fractions ( Figure 1A ). Area-under-the-curve analyses of cholesterol fractions showed a 50% decrease in very-low-density lipoprotein/ LDL cholesterol levels in both apoE -/-and DKO recipients compared with pre-BMT levels ( Figure IA and IB in the online-only Data Supplement; gray and open bars). These lipid changes were attributable to return to chow diet. However, in WT and MΦLRP1 -/-recipient mice, the corresponding decrease was 94% and 80% for very-lowdensity lipoprotein and LDL, respectively ( Figure IA and IB in the online-only Data Supplement; red and blue bars). This was due to the reintroduction of apoE, which has a strong hypolipidemic effect, and to the return to chow diet. Interestingly, HDL was 1.9-fold higher in MΦLRP1 -/-recipient mice compared to WT recipients ( Figure IC in the online-only Data Supplement). Immunoblots of serum from both WT and MΦLRP1
-/-recipient mice showed the presence of apoE and decreased apolipoprotein B100 levels compared to pre-BMT analyses ( Figure 1B) .
Expression of LRP1 in Atherosclerosis Regression
We evaluated the expression of LRP1 in atherosclerotic plaques in apoE -/-recipient mice euthanized 2 weeks after BMT (baseline) and in WT recipient mice undergoing regression for 10 weeks on a chow diet. Intraplaque LRP1 decreased in WT recipient mice during regression compared to baseline controls (Figure 2A ). Regressing plaques are known for having increased M2 versus M1 macrophages.
15,28 Thus, we compared Lrp1 gene expression in mouse peritoneal macrophages (MPMs) from WT mice polarized to either the inflammatory M1 phenotype using IFN-γ and LPS or the anti-inflammatory M2 phenotype with IL-4. Lrp1 was 3-fold higher in M1 macrophages compared to M2 (P<0.05) ( Figure 2B ). To determine whether elevated Lrp1 gene expression in the inflammatory M1 state was specific to mice, we treated human THP-1 monocytes with phorbol 12-myristate 13-acetate to differentiate them into macrophages. Differentiated THP-1 cells were then treated with IFN-γ and either LPS or IL-4 to stimulate M1 and M2 macrophages, respectively. Interestingly, LRP1 protein levels increased in phorbol 12-myristate 13-acetate-treated THP-1 cells compared to naïve THP-1 monocytes ( Figure 2C, left) . We also observed sustained LRP1 level increases in THP-1 macrophages treated with IFN-γ and LPS, and complete ablation of LRP1 protein in cells treated with IL-4 ( Figure 2C, right) .
Loss of Macrophage LRP1 Accelerates Plaque Regression
We evaluated atherosclerosis in WT and MΦLRP1 -/-recipient mice after 10 weeks on a chow diet to determine the role of macrophage LRP1 during regression. A Figure 3A) . Serum triglycerides were 108±33 mg/dL before BMT and decreased by 44% in WT recipients (61±16 mg/dL; P<0.01) and by 50% in MΦLRP1 -/-recipient mice (54±17 mg/dL; P<0.001) ( Figure 3B (Figure 3C and 3D) .
Macrophage LRP1 is protective during the progression of atherosclerosis in part due to its role in limiting apoptosis and accelerating efferocytosis. 22, 24 Cryosections from baseline, WT, and MΦLRP1 -/-recipient mice were stained for terminal deoxynucleotidyl transferase dUTP nick-end labeling to evaluate the levels of intraplaque apoptosis. There was no change in levels of apoptosis among baseline controls and mice undergoing regression ( Figure IIA and IIB in the online-only Data Supplement). We also determined the degree of efferocytosis in lesions by comparing the terminal deoxynucleotidyl transferase dUTP nick-end labeling-positive area within macrophages stained with Mac-2. Again, no differences were observed across the groups (Figure IIC in the online-only Data Supplement). Coinciding with these observations, no differences in necrotic core area were observed between groups ( Figure IID 
Loss of Macrophage LRP1 Increases Reverse Cholesterol Transport During Atherosclerosis Regression
Net efflux of cholesterol from plaques to the liver and its excretion through feces, a process known as RCT, are putative mechanisms of atheroma regression. To determine RCT in vivo, we injected WT, MΦLRP1
-/-, apoE -/-, and DKO -/-(DKO) recipient mice after 10 weeks on a chow diet. Pooled serum subjected to fast performance liquid chromatography as described in Methods. A, Total serum cholesterol (µg) for each fraction. B, Immunoblot using serum for apoB100 and apoE. Each data point reflects pooled serum from 2 to 3 mice. HDL indicates high-density lipoprotein; IDL, intermediate-density lipoprotein; LDL, low-density lipoprotein, and VLDL, very-low-density lipoprotein.
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macrophages loaded with 3 H-cholesterol acetylated LDL into the peritoneal cavity of BMT mice of matched donor genotype. Serum, feces, and liver were collected to determine the extent of reverse cholesterol transport, as described in Methods. All mice that received apoE complementation (recipients of WT and MΦLRP1
-/-marrow) demonstrated enhanced RCT in the liver and feces compared to apoE -/-and DKO recipients ( Figure 4A through  4C) . Total, liver, and feces RCT in MΦLRP1 -/-recipient mice was ≈1.4-fold higher than that of WT recipients (Figure 4B through 4D; P<0.01 ). There were no differences in RCT between apoE -/-and DKO recipient mice. In macrophages, tyrosine phosphorylation of an amino acid NPxY domain in LRP1 initiates a signaling cascade activating peroxisome proliferator-activated receptor γ and liver X receptor to regulate cholesterol homeostasis through the expression of ATP-binding cassette transporter subfamily A member 1 (ABCA1). 29 Thus, loss of LRP1 should correlate with reduced ABCA1 expression and diminished cholesterol efflux capacity. To determine whether the enhanced RCT in MΦLRP1 -/-recipient mice observed in vivo was due to macrophage cholesterol efflux, we isolated MPMs from WT, MΦLRP1 -/-, apoE -/-, and DKO mice. MPMs were loaded for 48 hours with acetylated LDL containing 3 H-cholesterol before being polarized to the M1 or M2 phenotype as described in Methods. Cholesterol-laden macrophages were exposed to apolipoprotein A1 for 24 hours to induce cholesterol efflux. While cholesterol efflux from M2 macrophages of MΦLRP1 -/-recipient mice was ≈1.2-fold higher compared to their M1 counterparts ( Figure 4E ), we did not observe differences in cholesterol efflux across the other genotypes. We also observed no changes in mRNA expression levels of key cholesterol transport proteins in M1 versus M2 macrophages from WT and MΦLRP1 -/-mice ( Figure 4F through 4H) .
Loss of Macrophage LRP1 Decreases Plaque Macrophage Content and M1 Cellularity
As previously mentioned, regressing plaques have reduced macrophage content, but also a preponderance of M2 versus M1 macrophages. Arginase-1 and arginase-2 are commonly used as markers for M2 and M1 macrophages, respectively. We evaluated M2 macrophage concentration in regressing plaques and determined that WT recipient mice had 3. + cells) ( Figure 5A and 5D ). There were no differences in M2 macrophage concentration between A, Plaques from baseline and wild-type (WT) recipient mice were stained with DAPI (blue), Mac-2 (red), and LRP1 (green), as described in Methods. Scale bar = 100 µm. B, Mouse peritoneal macrophages were isolated from WT mice (n=3) and polarized to the M1 or M2 phenotype, as described in Methods. Quantitative real-time polymerase chain reaction was used to determine mRNA levels of LRP1 and reported as fold change over the primed controls (Mo) (interferon-γ [IFN-γ] treated only; solid black line). Gene expression data are represented as mean±SEM, and the Wilcoxon signed rank test was performed to determine differences from Mo. The student t test was used to determine differences between genotypes. *P<0.05. C, THP-1 monocytes were differentiated to macrophages with phorbol 12-myristate 13-acetate treatment for 48 hours. Differentiated THP-1 macrophages were then primed with IFN-γ for 6 to 8 hours followed by treatment with either IFN-γ and lipopolysaccharides (LPS) or interleukin 4 (IL-4) for 12 hours, as described in Methods. LRP1 and β-Actin were visualized and quantified via Western blotting. ApoE indicates apolipoprotein DAPI, 4',6-diamidino-2-phenylindole; E; Mac-2, Galectin-3; Mo, primed controls; and PMA, phorbol 12-myristate 13-acetate.
WT and MΦLRP1
-/-recipient mice. We observed the same concentration of M1 macrophages in the plaques of WT recipient mice (47.6±4.1% of total CD68 + cells) as the baseline controls (45±4.3% of total CD68 + cells), whereas MΦLRP1 -/-recipient mice unexpectedly had an M1 concentration 36% less (28.6±3.7% of total CD68 + cells; P<0.0001) (Figure 5B and 5E ). This means that the plaques of MΦLRP1 -/-recipient mice had 40% fewer M1 macrophages relative to plaques of WT recipient mice (P<0.0001), even though the correction of dyslipidemia was similar in these 2 groups. Plaques from MΦLRP1 -/-recipient mice harbored a 4-fold higher M2/M1 ratio than baseline controls (P<0.001) ( Figure 5F ). No differences were observed in the M2/M1 phenotype ratio between baseline controls and WT recipients, or between WT and MΦLRP1 -/-recipient mice. Compared to baseline controls Atherosclerosis was developed in apoE -/-mice as described in Methods. After lethal irradiation, mice underwent bone marrow transplantation (BMT) from wild-type (WT) or MΦLRP1 -/-(low-density lipoprotein receptor-related protein 1 in macrophages) mice, and switched to chow diet for 10 weeks. ApoE -/-recipient mice were euthanized after 2 weeks on the chow diet and used as baseline. A, Total serum cholesterol and (B) total serum triglycerides from apoE -/-on Western diet for 12 weeks (before BMT), and from WT and MΦLRP1 -/-recipient mice after 10 weeks on the chow diet (mg/dL Figure 5C ). Regressing plaques from MΦLRP1 -/-recipient mice had 25% fewer CD68 + cells than those of their WT recipient counterparts (P<0.01).
Plaques from DKO recipient mice, which did not undergo regression, had more M2 and fewer M1 macrophages compared to baseline and apoE -/-recipient mice ( Figure IVA 
Regressing Plaques in MΦLRP1 -/-Recipients Show Accelerated CCR7-Dependent Macrophage Egress
Another mechanism of atherosclerosis regression is the CCR7-dependent macrophage egress from the plaque. 11, 12 We evaluated CCR7 expression in plaque macrophages ( Figure 6A -/-recipient mice also contained significantly more double-positive cells than apoE -/-lymph nodes. CCR7 + EdU + double-positive cells found in superficial cervical lymph nodes were negligible. In vitro, WT and MΦLRP1 -/-mouse peritoneal macrophages were first primed using IFN-γ (Mo), and then polarized to the M1 phenotype (via IFN-γ + LPS). A cohort of M1 macrophages was then switched to the M2 phenotype with IL-4. Ccr7 expression was determined , and apoE
-/-(DKO) mice were cultured with acetylated low-density lipoprotein (50 µg/mL) containing 3 H-cholesterol for 48 hours. After equilibration, macrophages were injected into mice of their respective donor genotype undergoing regression (chow diet). RCT was determined as described in Methods. , and DKO mice was determined, as described in Methods. WT and MΦLRP1 -/-MPMs were first primed (Mo), and then differentiated to M1 or M2 polarizations, as described in Methods. Quantitative real-time polymerase chain reaction was used to determine changes in gene expression of (F) ATP-binding cassette transporter subfamily A member 1 (ABCA1), (G) ATP-binding cassette transporter subfamily G member 1 (ABCG1), and (H) scavenger receptor class B type 1 (SRB1) and reported as fold change over interferon γ primed macrophages (Mo; black dashed line). Gene expression data are presented as mean±SEM. For RCT, 1-way ANOVA with Bonferroni post hoc tests was used to compare effects across genotypes. For cholesterol efflux and gene expression, 2-way ANOVA with Sidak multiple comparisons test was used to compare effects across genotypes and macrophage subtypes. ***P<0.001, **P<0.01, *P<0.05. using qRT-PCR. Expression of Ccr7 was increased 5.5-fold in WT M1 macrophages and 20-fold in MΦLRP1 -/-M1 macrophages compared to their respective Mo control (P<0.05) ( Figure 6D ). Also, MΦLRP1
-/-M1 macrophages displayed 2.6-fold higher levels of Ccr7 than WT M1 counterparts, but this did not reach statistical significance. Feig et al have shown that the murine CCR7 gene contains binding sites for sterol regulatory element binding (SREB) proteins (SREBPs), specifically SREB1, and treatment of the murine macrophage cell line RAW264.7 with statins induces Srebf1 and Srebf2 expression to upregulate CCR7. 30 Thus, we polarized MPMs from WT and MΦLRP1
-/-mice to the M1 phenotype and measured mRNA expression of Srebf1 and Srebf2. Indeed, M1 macrophages from MΦLRP1 -/-mice had a 2-fold increase in Srebf1 compared to WT M1 macrophages; no differences were observed in Srebf2 expression ( Figure 6E ).
To determine whether increased monocyte recruitment to the plaque could explain the increased egress, we labeled CD11b monocytes from WT and MΦLRP1 -/-donor mice with fluorescent CellTracker Green 5-chloromethylfluorescein diacetate and injected 2.0×10 6 cells into mice of their respective genotype undergoing regression. After 72 hours, mice were euthanized, and aortic root cryosections were stained for macrophages using CD68. While plaques from both WT and MΦLRP1 -/-recipient mice contained CD68 + 5-chloromethylfluorescein diacetate-positive double-positive staining, there was no difference between genotypes ( Figure 6F and 6G) .
DISCUSSION
In this study we identify an unexpected role for macrophage LRP1 during atherosclerosis regression in the mouse. We observed decreased LRP1 expression in mouse and human macrophages polarized to an antiinflammatory state compared to their proinflammatory counterpart. We transplanted WT and MΦLRP1 -/-bone marrow into apoE -/-mice with established plaques, thus reintroducing apoE to correct the hyperlipidemia and drive regression of atherosclerosis. After 10 weeks of the regressive environment, we observed diminished intraplaque LRP1 in WT recipients, and that loss of macrophage LRP1 accelerates plaque regression independently of plasma lipid levels. During regression we observed elevated serum apoE and HDL, and increased RCT in MΦLRP1 -/-recipient mice, relative to their WT recipient controls. Extensive plaque characterization revealed a reduction in CD68 + cell counts and elevated M2/M1 macrophage ratios in MΦLRP1
-/-recipient mice 
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caused by selective loss of inflammatory M1 macrophages. There were no differences in plaque apoptosis or efferocytosis. Finally, plaques from mice lacking macrophage LRP1 had increased CCR7 + macrophage staining, and CCR7 + EdU + double-positive macrophages accumulated in nearby mediastinal lymph nodes, not in control lymph nodes, which was independent of monocyte recruitment. In fact, inflammatory M1 macrophages from MΦLRP1 -/-mice display increased Srebf1 gene expression compared to WT M1 controls, a transcription factor directly implicated in CCR7 expression.
Models of atherosclerosis regression, studied in the mouse for nearly 2 decades, 31 rely on rapid correction of dyslipidemia in animals with established plaques. 8, 30, 32 Key mechanisms driving regression include (1) increased reverse cholesterol transport, 7, 33 (2) enrichment of anti-inflammatory M2 macrophages, (3) depletion of inflammatory M1 macrophages, 15, 16, 28 (4) upregulated macrophage CCR7 expression and CCR7-dependent egress of resident macrophages from plaques to nearby lymph nodes, 12, 17 and (5) suppressed monocyte infiltration into the atheroma. 8 Daugherty et al provide detailed recommendations on the design and interpretation of mouse models of atherosclerosis, as well as regression. 34 We have developed a model of murine regression using apoE complementation from bone marrow cells (WT and MΦLRP1 -/-donors) into apoE -/-mice with established plaques. Bone marrow apoE is sufficient to correct dyslipidemia in apoE -/-mice 27 ( Figure 1 ) and drive regression of atherosclerotic plaques (Fig- -/-(DKO) donor mice were injected into recipient mice of their respective genotype on chow diet (n=4 to 6 mice per genotype). After 72 hours, mice were euthanized, and in vivo macrophage egress into the mediastinal lymph nodes (Med.) and superficial cervical control lymph nodes (SC) was determined via fluorescence-activated cell sorting analysis of CCR7 + EdU + double-positive cells, as described in Methods. ANCOVA was performed to determine differences in Med. lymph nodes using donor genotype as the independent variable and paired SC lymph nodes as the covariate. The Tukey post hoc test was used to determine pairwise differences in Med. lymph nodes. *P<0.05. D, qRT-PCR was used to determine Ccr7 expression in mouse peritoneal macrophages (n=5 to 6 per genotype) primed with interferon γ (50 ng/mL; Mo) (dark red and dark blue bars) or differentiated to M1 (open bars), or switched from M1 to M2 (pink and light blue bars), as described in Methods. Data are presented as mean±SEM, and the Wilcoxon signed rank test was performed to determine differences from Mo (*P<0.05). An unpaired Mann-Whitney test was performed to determined individual differences between groups ( & P<0.05). E, Quantitative real-time polymerase chain reaction was used to determine changes in Srebf1 and Srebf2 expression in mouse peritoneal macrophages isolated from WT and MΦLRP1 -/-mice (n=6 and n=5, respectively) and differentiated to the M1 phenotype. Data are represented as mean±SEM and normalized to the WT recipient group. The unpaired Mann-Whitney test was used to compare differences in gene expression between genotypes. *P<0.05. CD11b monocytes isolated from WT and MΦLRP1 -/-donor mice were labeled with CellTracker Green 5-chloromethylfluorescein diacetate and injected intravenously into WT and MΦLRP1 -/-recipient mice (n=3 and n=4, respectively) undergoing regression (2×10 6 monocytes per mouse). After 72 hours, mice were euthanized, and aortic sinus tissue was sectioned. F, Aortic sinus sections were immunofluorescently stained for CD68 (red) and DAPI (blue), as described in Methods. Scale bar = 100 µm. G, Monocyte recruitment was determined by counting newly recruited monocyte/macrophages (green) positive for CD68 and normalized to lesion area. A Student t test was performed to determine differences in monocyte recruitment. CCR7 indicates C-C chemokine receptor type 7; M1, inflammatory macrophages; M2, anti-inflammatory macrophages; and Mo, primed macrophages. Although there were no differences in plasma lipids between WT and MΦLRP1 -/-recipient mice, loss of macrophage LRP1 increased serum apoE and HDL cholesterol levels (Figure 1 and Figure I in the online-only Data Supplement). Macrophage-derived apoE is known to have local protective effects on the plaque, 35 and thus may have contributed to the inflammation resolution and accelerated regression observed in this study. In fact, previous regression studies have reported a direct correlation between plasma apoE concentration and plaque size. 31 Elevated serum HDL cholesterol in MΦLRP1 -/-recipient mice compared to WT recipient controls may relate to the observed increases in RCT ( Figure 4 ) and to accelerated plaque resolution ( Figure 5 ). Regression has also been achieved in mouse models through HDL-based interventions (ie, via apoA-I overexpression) promoting RCT from macrophage foam cells. 36, 37 It is unclear why loss of LRP1 in macrophages would directly promote RCT, considering that we observed no differences in cholesterol efflux or in the expression of the key cholesterol transport proteins ATP-binding cassette transporter subfamily A member 1 (ABCA1), ATP-binding cassette transporter subfamily G member 1 (ABCG1), and scavenger receptor class B type 1 (SRB1) between WT and MΦLRP1 -/-macrophages ( Figure 3E through 3H) . However, previous studies have implicated functional macrophage egress through the lymphatic system as a modulator of RCT. 38 Macrophage clearance from the atherosclerotic plaque is a hallmark of regression. In this study, plaques from MΦLRP1 -/-recipient mice had fewer CD68 + cells. Specifically, MΦLRP1
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-/-recipient mice showed similar numbers of M2 but fewer M1 macrophages than WT recipient controls, suggesting that M1 cells of MΦLRP1 -/-recipient mice undergo enhanced egress, enhanced necrosis, decreased monocyte recruitment, or perhaps all 3 (Figure 5A through 5E ). During progression of atherosclerosis, macrophage LRP1 acts as an efferocytosis receptor for "eat me" signals, such as calreticulin. Absence of LRP1 may negate the effects of blocking "don't eat me" signals such as CD47. 39, 40 However, the lack of differences in monocyte recruitment ( Figure 6F and 6G) , apoptosis, necrosis, and efferocytosis in plaques of regressing mice supports a potential role for enhanced egress ( Figure IIA though IID in the online-only Data Supplement). Inhibiting CCR7-dependent macrophage egress with blocking antibodies to its ligands, CCL19 and CCL21, disrupts plaque regression. 12 A previous study on macrophage chemotaxis reported similar CCR7 protein levels in M1 and M2 macrophages. However, only M1 macrophages responded to CCL19 and CCL21. 41 The CCR7 gene contains binding sites for the SREBPs in both humans and mice, and its expression is directly modulated by SREBPs. 11 Interestingly, SREBPs modulate LRP1 expression in human macrophage foam cells. 42 We and others have reported that LRP1 -/-macrophages have reduced lipoprotein uptake both in vivo and in vitro, 21, 42, 43 a functional consequence that could lead to SREBP activation. These reports, together with our observations of increased CCR7 + macrophages in MΦLRP1 -/-recipient plaques ( Figure 6A and 6B ), enhanced accumulation of CCR7 + EdU + macrophages in the mediastinal lymph nodes of MΦLRP1 -/-recipient mice ( Figure 6C and Figure V in the online-only Data Supplement), and elevated Srebf1 gene expression in LRP1 -/-M1 macrophages ( Figure 6E ) suggest that the mechanism of M1 macrophage depletion is a CCR7-dependent egress from plaques. On the other hand, in another apoE complementation model, the genetic knockdown of CCR7 did not affect regression, and loss of macrophages in the plaque was attributed to reduced monocyte infiltration rather to increased egress. 8 Our results show no difference in monocyte recruitment between WT and MΦLRP1 -/-recipient mice ( Figure 6F and 6G) . A limitation in our study was the inability to directly track the emigration of EdUlabeled monocyte/macrophages from the plaque to the lymph nodes. Thus, use of CCL19/21 blocking antibodies during regression will be necessary to determine whether CCR7 is responsible for the increased egress and subsequent accelerated plaque regression in our study.
The expression of LRP1 in multiple cell types, including macrophages, has been characterized as protective against atheroma formation in murine models of disease progression. Its loss in smooth muscle cells leads to worsened atherosclerosis and formation of aortic aneurysms, 44, 45 whereas its loss in macrophages accelerates plaque growth caused by decreased M2/M1 plaque macrophage ratios, elevated circulating Ly6C hi monocytes, enhanced susceptibility to apoptosis, and impaired efferocytosis. 21, 22, 24 Our finding that loss of macrophage LRP1 accelerates plaque resolution during atherosclerosis regression may be due to the dual role of LRP1 in mediating the effects of tumor necrosis factor α on vascular inflammation and in balancing the effects of CD47 on efferocytosis. 39, 40 Our results open the way for more focused investigations of the molecular pathways controlling arterial wall homeostasis, and are a stark reminder that the biology of plaque regression is regulated by forces that are different than, and maybe even opposite to, those driving plaque formation and growth. Our results show that LRP1 plays a complex role in limiting inflammation and suggest that inflammation resolution may prove detrimental during regressive conditions.
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